Abstract 145P
Background
IO ± chemotherapy (CT) is first-line therapy for mNSCLC without actionable mutations. We aimed to identify a genomic signature potentially predicting resistance to IO using NGS.
Methods
Pts with mNSCLC who received IO or CT/IO were eligible. NGS was performed by TSO500HT® assay (DNA [522 genes], RNA [55 genes], Tumor Mutational Burden, Microsatellite Instability) or Oncomine Focus Assay® (DNA, 35 genes) plus Archer’s FusionPlex Lung Panel® (RNA, 17 genes), according to quality/quantity cellularity. A least absolute shrinkage and selection operator (LASSO) Cox regression was conducted to choose genes. The correlation between LASSO-selected genes and progression-free survival (PFS) was evaluated by univariable Cox regression. A risk score was derived using regression coefficients of significant genes in the multivariable analysis. Pts were divided into two groups based on the median risk score (0 vs >0). The risk score was evaluated in a multivariable model including clinical features.
Results
56 pts were retrospectively included. 32 (57%) received CT/IO and 23 (43%) IO. Median follow-up was 10.4 months. Among 346 genes, 15 resulted potentially predictive of PFS. At univariable analysis, 6 genes were significantly correlated to PFS: AKT3 (HR 40.39, 95% IC 5.58-292.30, p<0.001), ARID5B (HR 4.98, 95% IC 1.11-22.24, p=0.04), CD276 (HR 14.33, 95% IC 2.60-78.99, p=0.002), PAX8 (HR 8.33, 95% IC 1.78-38.95, p=0.007), PDGFRB (HR 4.88, 95% IC 1.42-16.75, p=0.01) and RICTOR (HR 3.82, 95% IC 1.08-13.57, p=0.04). In the multivariable analysis PAX8 was excluded and a genomic signature with 5 genes was considered. PFS was significantly different in the two risk groups: HR 13.56, 95% IC 5.30-34.67, p<0.001, with a median PFS of 1.64 (95% IC 0.76-NA) vs 13.25 months. (95% IC 10.88-NA). The genomic signature remained prognostic in a multivariable model including age, smoke, histology and regimen (HR 15.71; 95% IC 5.19-47.52, p<0.001).
Conclusions
A genomic signature including AKT3, ARID5B, CD276, PDGFRB and RICTOR alterations was significantly associated with shorter PFS in pts receiving IO. Validation in external cohort is ongoing.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Medical Oncology Unit, Fondazione Policlinico Agosto Gemelli.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
113P - Evaluation of effects of tissue preservation methods on the proteome abundance through deep proteomics of breast cancer tissue
Presenter: Shashwati parihari
Session: Cocktail & Poster Display session
Resources:
Abstract
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract